Literature DB >> 20861290

A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis.

Anna P Ralph1, Muhamed Ardian, Andri Wiguna, Graeme P Maguire, Niels G Becker, Glen Drogumuller, Michael J Wilks, Govert Waramori, Emiliana Tjitra, Enny Kenagalem, Gysje J Pontororing, Nicholas M Anstey, Paul M Kelly.   

Abstract

BACKGROUND: The grading of radiological severity in clinical trials in tuberculosis (TB) remains unstandardised. The aim of this study was to generate and validate a numerical score for grading chest x-ray (CXR) severity and predicting response to treatment in adults with smear-positive pulmonary TB.
METHODS: At a TB clinic in Papua, Indonesia, serial CXRs were performed at diagnosis, 2 and 6 months in 115 adults with smear-positive pulmonary TB. Radiographic findings predictive of 2-month sputum microscopy status were used to generate a score. The validity of the score was then assessed in a second data set of 139 comparable adults with TB, recruited 4 years later at the same site. Relationships between the CXR score and other measures of TB severity were examined.
RESULTS: The estimated proportion of lung affected and presence of cavitation, but not cavity size or other radiological findings, significantly predicted outcome and were combined to derive a score given by percentage of lung affected plus 40 if cavitation was present. As well as predicting 2-month outcome, scores were significantly associated with sputum smear grade at diagnosis (p<0.001), body mass index, lung function, haemoglobin, exercise tolerance and quality of life (p<0.02 for each). In the validation data set, baseline CXR score predicted 2-month smear status significantly more accurately than did the proportion of lung affected alone. In both data sets, CXR scores decreased over time (p<0.001).
CONCLUSION: This simple, validated method for grading CXR severity in adults with smear-positive pulmonary TB correlates with baseline clinical and microbiological severity and response to treatment, and is suitable for use in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861290     DOI: 10.1136/thx.2010.136242

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  83 in total

1.  Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns.

Authors:  Chin-Chung Shu; Chih-Hsin Lee; Chia-Lin Hsu; Jann-Tay Wang; Jann-Yuan Wang; Chong-Jen Yu; Li-Na Lee
Journal:  Lung       Date:  2011-09-29       Impact factor: 2.584

2.  Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study.

Authors:  Caian L Vinhaes; Deivide Oliveira-de-Souza; Paulo S Silveira-Mattos; Betania Nogueira; Ruiru Shi; Wang Wei; Xing Yuan; Guolong Zhang; Ying Cai; Clifton E Barry; Laura E Via; Kiyoshi F Fukutani; Bruno B Andrade; Katrin D Mayer-Barber
Journal:  Cytokine       Date:  2019-06-18       Impact factor: 3.861

3.  Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.

Authors:  N Padayatchi; M Gopal; R Naidoo; L Werner; K Naidoo; I Master; M R O'Donnell
Journal:  J Antimicrob Chemother       Date:  2014-06-30       Impact factor: 5.790

4.  Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring.

Authors:  Ines Labugger; Jan Heyckendorf; Stefan Dees; Emilia Häussinger; Christian Herzmann; Thomas A Kohl; Elvira Richter; Eric Rivera-Milla; Christoph Lange
Journal:  Infection       Date:  2016-10-31       Impact factor: 3.553

5.  Characteristics of Poor Tuberculosis Treatment Outcomes among Patients with Pulmonary Tuberculosis in Community Hospitals of Thailand.

Authors:  Sakarn Charoensakulchai; Manasak Limsakul; Inkharat Saengungsumalee; Sirawich Usawachoke; Aticha Udomdech; Anintita Pongsaboripat; Wisit Kaewput; Boonsub Sakboonyarat; Ram Rangsin; Picha Suwannahitatorn; Mathirut Mungthin; Phunlerd Piyaraj
Journal:  Am J Trop Med Hyg       Date:  2020-03       Impact factor: 2.345

6.  Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum.

Authors:  Bo Deng; Wei Huang; Qun-You Tan; Xiao-Qing Fan; Yao-Guang Jiang; Ling Liu; Ya-Yi Zhong; Yong-Gang Liang; Ru-Wen Wang
Journal:  Mol Diagn Ther       Date:  2011-02-01       Impact factor: 4.074

7.  High Prevalence and Heterogeneity of Diabetes in Patients With TB in South India: A Report from the Effects of Diabetes on Tuberculosis Severity (EDOTS) Study.

Authors:  Hardy Kornfeld; Kim West; Kevin Kane; Satyavani Kumpatla; Rajesh Roy Zacharias; Carlos Martinez-Balzano; Wenjun Li; Vijay Viswanathan
Journal:  Chest       Date:  2016-03-10       Impact factor: 9.410

Review 8.  Assessment of treatment response in tuberculosis.

Authors:  Neesha Rockwood; Elsa du Bruyn; Thomas Morris; Robert J Wilkinson
Journal:  Expert Rev Respir Med       Date:  2016-03-31       Impact factor: 3.772

9.  Impaired pulmonary nitric oxide bioavailability in pulmonary tuberculosis: association with disease severity and delayed mycobacterial clearance with treatment.

Authors:  Anna P Ralph; Tsin W Yeo; Cheryl M Salome; Govert Waramori; Gysje J Pontororing; Enny Kenangalem; Emiliana Tjitra; Richard Lumb; Graeme P Maguire; Ric N Price; Mark D Chatfield; Paul M Kelly; Nicholas M Anstey
Journal:  J Infect Dis       Date:  2013-06-03       Impact factor: 5.226

10.  Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis.

Authors:  A Singanayagam; K Manalan; D W Connell; J D Chalmers; S Sridhar; A I Ritchie; A Lalvani; M Wickremasinghe; O M Kon
Journal:  Int J Tuberc Lung Dis       Date:  2016-12       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.